Skip to search formSkip to main contentSkip to account menu

DT56a

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
To determine the metabolic and immunological effects of the oral administration of DT56a, an enzymatic isolate of soybeans. 
2013
2013
Background: Hormone therapy (HT) is the treatment of choice for the alleviation of menopausal symptoms; concerns, however, about… 
2011
2011
Objective:The purpose of this study was to assess the effect of DT56a (Femarelle), a selective estrogen receptor modulator, on… 
2009
2009
Objective: The natural selective estrogen receptor modulator DT56a (Femarelle), derived from soybean, has been shown to relieve… 
2007
2007
2005
2005
Objective  DT56a is a natural compound for the treatment of menopausal symptoms and osteoporosis. The aim of this study was to… 
2004
2004
OBJECTIVE In a previous study treatment with a daily standard dose of Femarelle (644 mg/day) resulted in a significant elevation… 
2003
2003
Objective To evaluate the efficacy of Tofupill/Femarelle (DT56a), a novel phyto-selective estrogen receptor modulator (SERM), in… 
2003
2003
The novel natural product DT56a (Secure Pharmaceuticals, Yavne, Israel), derived from soybean, has been shown to relieve…